Executive Summary
As pharmaceutical companies brace for potential DTC advertising restrictions under the new regulatory environment, commercial teams may be tempted to turn to their most utilized digital alternative: ramping up email campaigns to healthcare providers. This strategy appears logical—if you can’t reach patients directly, reach more doctors more frequently.
However, the data reveals some important considerations. Pharmaceutical emails to HCPs achieve just 9.93% open rates¹ and providers receive an onslaught of them daily. On top of this, providers receive 77+ daily EMR notifications². For providers, email volume is contributing to record levels of burnout – the exact opposite intention of commercial teams. HCP Email has become a saturated channel with declining effectiveness and increasing email volume, though tempting, simply contributes to the problem.
The Bottom Line: More email may not be the most effective response to DTC restrictions—and could be counterproductive for HCP engagement and overall pharmaceutical marketing effectiveness.
The Email Reality Check
When regulatory uncertainty threatens traditional channels, the instinctive response is often “more of something else.” For pharmaceutical marketers facing potential DTC restrictions, that “something else” has become email—contributing to some concerning trends.
Since 2019, pharmaceutical email volume to HCPs has increased significantly as companies pivoted digital-first during COVID-19 and maintained those volumes despite declining effectiveness.
Yet performance tells a different story. Pharmaceutical emails to HCPs achieve just 9.93% open rates—among the worst-performing marketing communications across industries. Meanwhile, primary care physicians receive 77 daily inbox notifications from EMR systems alone, requiring nearly an hour of daily processing time before considering any marketing messages.
The Math That Doesn’t Add Up
Let’s examine the mathematical reality of email dependence versus alternatives:
Email Performance Reality:
- Open rate: 9.93%
- Industry ranking: Among the lowest across all sectors
- HCP sentiment: Growing fatigue and resistance
Face-to-Face Alternative:
- Research shows face-to-face requests are 34 times more effective than email**
- HCP preference: Face-to-face remains the top preference for professional communication
- Engagement quality: Significantly higher conversion and relationship-building potential
The Strategic Misalignment: Companies are scaling their investment in the channel that ranks among HCPs’ lower preferences because of its cost effectiveness, ease of deployment and measurability. While the logic looks good in a plan, the concern is over-saturation as an industry and under-investment in the HCP-centered approaches that drive meaningful engagement.
When Volume Creates Problems
The pharmaceutical industry’s increased email volume may be creating unintended consequences beyond just inefficiency.
Recent industry research reveals concerning trends:
- Analysis of 7.9 million pharmaceutical emails shows campaigns exceeding 16 emails drop to less than 2% engagement while generating the highest unsubscribe rates^^
- HCPs report increasing overwhelm from promotional content
- Email overload research indicates that high email volume can decrease engagement across ALL channels, including face-to-face interactions
High-volume email strategies may inadvertently impact overall brand relationships beyond just email performance.
The Investment Mismatch
Perhaps the most significant issue is how email fixation misdirects strategic thinking and resource allocation.
Current Investment Patterns:
- The vast majority of marketing funds still go to sales representatives
- Digital channel investment focuses heavily on email
- Face-to-face interactions receive declining strategic focus despite remaining highly effective
HCP Preferences Tell a Different Story:
- Face-to-face meetings remain the top preference for professional engagement
- In-person conferences rank highly for information gathering
- Email, while used, ranks lower in preference surveys
- Only 27% of HCPs feel pharmaceutical companies communicate with them in a relevant and personalized manner***
What Actually Works
Companies seeing better results are focusing on strategies that amplify effective channels rather than scaling ineffective ones:
- Enhanced Face-to-Face Strategy: Rather than hoping more emails will generate appointments, leading companies optimize their face-to-face engagement through better targeting, timing, and resourcefulness to ultimately drive toward the right expert, right message at the right time. This includes strategic investment in platforms and channels that facilitate face-to-face interactions—including conference participation, professional society partnerships, and digital platforms that connect pharmaceutical teams with HCPs seeking real-time engagement. The focus shifts from pushing for meetings through email volume to being available to HCPs where and when they want to engage.
- Preference-Driven Engagement: Companies have spent more than a decade capturing and maintaining HCP email opt-ins. At its surface, and when combined with email engagement trends, this is viewed as HCP preference and permission. Leading companies enrich this with additional, first-party HCP preference data to build truly HCP-centric engagement strategies that take into account all channels, timing, content and a jobs to be done framework.
- Quality-Focused Content Strategy: Companies breaking through the relevance barrier focus on valuable, educational content delivered through HCP-preferred channels rather than promotional messaging via oversaturated digital channels. Providers need useful content that solves specific problems delivered at the right time and in a channel where they will be receptive to it.
- Integrated Channel Orchestration: The most effective pharmaceutical marketing uses email strategically—as part of integrated campaigns that build toward high-value interactions rather than as a primary engagement vehicle.
The Strategic Opportunity
Here’s a counterintuitive perspective: potential restrictions on pharmaceutical marketing channels might force the industry toward more effective engagement strategies.
Companies currently investing heavily in channels that generate poor engagement could be compelled to focus on platforms and approaches that HCPs actually prefer. Regulatory pressure becomes a catalyst for strategic evolution rather than a barrier to overcome.
The Strategic Reset Framework:
- Shift from volume-based to value-based HCP engagement
- Invest in optimizing high-preference channels like face-to-face interactions
- Focus on quality content and genuine relationship building
- Reduce digital noise while increasing meaningful connection
The Path Forward
For pharmaceutical commercial leaders, the current landscape demands strategic reconsideration.
- Stop: Defaulting to increased email volume as the primary digital response
- Start: Investing in platforms and strategies that amplify HCP-preferred engagement methods
- Focus: On interaction quality and HCP-stated preferences
- Measure: Relationship strength and engagement quality, not just volume metrics
The regulatory environment threatening DTC advertising simultaneously creates opportunities for companies smart enough to recognize that more email may not be the solution—better, more targeted engagement is.
The companies that will thrive are those that use this transition period to build genuine, preference-powered relationships with healthcare providers through the channels and methods providers actually want to use.
For pharmaceutical companies ready to move beyond email dependence toward effective HCP engagement strategies, the current uncertainty represents not a threat, but an opportunity to build competitive advantages that will outlast any specific channel or regulation.
